Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2021 | NERO trial: PARP inhibitors for chemosensitive NSCLC

Dean Fennell • 19 Apr 2021
BTOG 2021
Lung Cancer Non-Small Cell Lung Cancer Olaparib
NERO

Dean Fennell, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, shares an update on the randomized Phase II/III NERO study (NCT01788332) investigating PARP inhibitors in patients with non-small cell lung cancer (NSCLC) who have previously responded to chemotherapy. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

More from Dean Fennell

1:14
ATOMIC: treating mesothelioma with an arginine-degrading enzyme and combination chemotherapy
Dean Fennell • 27 Apr 2023
3:34
Role of immunotherapy in the management of mesothelioma
Dean Fennell • 31 Mar 2023
6:43
Personalized medicine in mesothelioma
Dean Fennell • 31 Mar 2023
1:54
Abemaciclib in patients with p16ink4a negative, relapsed mesothelioma
Dean Fennell • 21 May 2021

Related Videos

3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals